• Transplant Tips, Talks, and Timing for Myelofibrosis

  • Oct 3 2024
  • Length: 27 mins
  • Podcast

Transplant Tips, Talks, and Timing for Myelofibrosis

  • Summary

  • Join Drs Tania Jain and Jeanne Palmer as they discuss their approach to transplant in myelofibrosis.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999597. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Myelofibrosis and Survival Prognostic Models: A Journey Between Past and Future https://pubmed.ncbi.nlm.nih.gov/36983189/

    DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

    Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

    Posttransplant Cyclophosphamide vs Tacrolimus-based GVHD Prophylaxis: Lower Incidence of Relapse and Chronic GVHD https://pubmed.ncbi.nlm.nih.gov/37156098/

    A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

    Advances in Pharmacotherapy for Myelofibrosis: What Is the Current State of Play? https://pubmed.ncbi.nlm.nih.gov/38738513/

    ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38201581/

    Superior Outcomes With Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - A Comparative Analysis by CIBMTR https://ashpublications.org/blood/article/138/Supplement%201/912/482649/Superior-Outcomes-with-Fludarabine-Busulfan-Flu-Bu

    Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis With Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35158092/

    Anti-T-Lymphocyte Globulin Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis After Matched Related or Unrelated Donor Transplantation https://pubmed.ncbi.nlm.nih.gov/38773281/

    Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/

    Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/31288096/

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Transplant Tips, Talks, and Timing for Myelofibrosis

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.